We are live on ! Find out more
NVO

Novo Nordisk

564 hedge funds and large institutions have $8.88B invested in Novo Nordisk in 2019 Q3 according to their latest regulatory filings, with 55 funds opening new positions, 179 increasing their positions, 211 reducing their positions, and 46 closing their positions.

New
Increased
Maintained
Reduced
Closed

68% more call options, than puts

Call options by funds: $79.2M | Put options by funds: $47.1M

20% more first-time investments, than exits

New positions opened: 55 | Existing positions closed: 46

13% more funds holding in top 10

Funds holding in top 10: 89 (+1)

1% more funds holding

Funds holding: 559564 (+5)

0% less capital invested

Capital invested by funds: $8.89B → $8.88B (-$10.8M)

0.2% less ownership

Funds ownership: 18.73%18.53% (-0.2%)

15% less repeat investments, than reductions

Existing positions increased: 179 | Existing positions reduced: 211

Holders
564
Holders Change
+5
Holders Change %
+0.89%
% of All Funds
12.37%
Holding in Top 10
9
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+12.5%
% of All Funds
0.2%
New
55
Increased
179
Reduced
211
Closed
46
Calls
$79.2M
Puts
$47.1M
Net Calls
+$32.1M
Net Calls Change
+$335K
Name Holding Trade Value Shares
Change
Change in
Stake
RJA
26
Raymond James & Associates
Florida
$62.6M +$965K +38,150 +2%
AAMU
27
Amundi Asset Management US
Massachusetts
$60.9M -$36.6M -1,447,362 -38%
Alyeska Investment Group
28
Alyeska Investment Group
Illinois
$60.8M +$37.6M +1,485,828 +172%
Jennison Associates
29
Jennison Associates
New York
$58M -$5.49M -217,086 -9%
Adage Capital Partners
30
Adage Capital Partners
Massachusetts
$56.9M -$25.3M -1,000,000 -31%
MG
31
Markel Group
Virginia
$55.6M
SC
32
Saturna Capital
Washington
$55.3M +$84.6K +3,344 +0.2%
Bank of New York Mellon
33
Bank of New York Mellon
New York
$55.1M +$583K +23,036 +1%
Goldman Sachs
34
Goldman Sachs
New York
$53.9M +$2.26M +89,452 +4%
Envestnet Asset Management
35
Envestnet Asset Management
Illinois
$53M +$2M +79,220 +4%
Balyasny Asset Management
36
Balyasny Asset Management
Illinois
$48.3M +$33.2M +1,313,966 +236%
Morgan Stanley
37
Morgan Stanley
New York
$43.5M +$1.4M +55,240 +3%
UCFA
38
United Capital Financial Advisors
Texas
$39.2M +$479K +18,946 +1%
Dimensional Fund Advisors
39
Dimensional Fund Advisors
Texas
$38.7M -$22.8K -900 -0.1%
CCM
40
Camber Capital Management
Massachusetts
$36.2M +$35.4M +1,400,000 New
JP Morgan Chase
41
JP Morgan Chase
New York
$29.1M -$14.2K -560 -0%
PNC Financial Services Group
42
PNC Financial Services Group
Pennsylvania
$24.4M -$380K -15,020 -2%
Russell Investments Group
43
Russell Investments Group
United Kingdom
$23.8M -$220K -8,702 -0.9%
Fidelity Investments
44
Fidelity Investments
Massachusetts
$23.7M -$325K -12,842 -1%
SFM
45
Sphera Funds Management
Israel
$23.3M +$22.8M +900,000 New
UBS Group
46
UBS Group
Switzerland
$22.8M -$12.2M -481,876 -35%
Millennium Management
47
Millennium Management
New York
$22.7M -$6.9M -272,912 -24%
Two Sigma Investments
48
Two Sigma Investments
New York
$22M +$15.7M +621,826 +271%
AIA
49
Avalon Investment & Advisory
Texas
$21.9M +$164K +6,472 +0.8%
PFM
50
Parsec Financial Management
North Carolina
$20.5M -$217K -8,564 -1%

NVO Hedge Fund Activity: Q3 2019 in Review

564 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q3 2019, worth a combined $8.88B — down 0.12% from $8.89B a quarter earlier.

Buyers outnumbered sellers: 55 funds opened new NVO positions and 46 closed out — a net gain of 9 holders — while 179 added to existing stakes and 211 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $115M. The largest seller was BlackRock, cutting an estimated $83.1M.

  • 564 institutional investors held Novo Nordisk (NVO) as of Q3 2019, up from 559 in Q2 2019.
  • Funds reported $8.88B of Novo Nordisk stock for Q3 2019, down 0.12% quarter-over-quarter.
  • 55 funds opened new Novo Nordisk positions in Q3 2019 and 46 closed out, a net change of +9 holders.
  • The largest Novo Nordisk buyer in Q3 2019 was Renaissance Technologies, an estimated $115M added.
  • The largest Novo Nordisk seller in Q3 2019 was BlackRock, an estimated $83.1M sold.

Based on aggregated 13F filings for Q3 2019.